A Look at Axogen (AXGN) Valuation Following FDA Avance Delay and Securities Law Probe [Yahoo! Finance]
Axogen, Inc. (AXGN)
Last axogen, inc. earnings: 2/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.axogeninc.com
Company Research
Source: Yahoo! Finance
The announcement pushed shares down over 9%, and it sparked a securities law investigation. See our latest analysis for Axogen. After months of steady total shareholder return, Axogen's recent volatility stands out as investors respond to both the FDA delay and fresh legal scrutiny. While share price momentum has cooled near $17.88, the company's three-year total shareholder return of roughly 58% highlights a longer-term growth narrative that has weathered recent turbulence. If you're looking for the next healthcare innovator with untapped potential, there is a whole landscape to explore. See the full list for free with our See the full list for free. With shares still sitting more than 38% below analyst price targets after recent swings, is the market providing investors with a rare entry point on Axogen, or are expectations for future growth already fully reflected? Most Popular Narrative: 27.7% Undervalued Compared to Axogen's most recent close at $17.88, the widely fol
Show less
Read more
Impact Snapshot
Event Time:
AXGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXGN alerts
High impacting Axogen, Inc. news events
Weekly update
A roundup of the hottest topics
AXGN
News
- AxoGen (NASDAQ:AXGN) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
- AxoGen (NASDAQ:AXGN) had its "buy" rating reaffirmed by analysts at Lake Street Capital.MarketBeat
- AxoGen (NASDAQ:AXGN) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
- Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx) [Yahoo! Finance]Yahoo! Finance
- Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)GlobeNewswire
AXGN
Earnings
- 10/29/25 - Beat
AXGN
Sec Filings
- 12/4/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form 144
- AXGN's page on the SEC website